Equities analysts expect Hologic, Inc. (NASDAQ:HOLX) to announce earnings of $0.49 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for Hologic’s earnings. The highest EPS estimate is $0.50 and the lowest is $0.48. Hologic reported earnings of $0.51 per share in the same quarter last year, which suggests a negative year over year growth rate of 3.9%. The company is expected to issue its next earnings report on Wednesday, July 26th.
On average, analysts expect that Hologic will report full year earnings of $2.01 per share for the current fiscal year, with EPS estimates ranging from $1.99 to $2.02. For the next fiscal year, analysts anticipate that the company will report earnings of $2.22 per share, with EPS estimates ranging from $2.11 to $2.35. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Hologic.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.46 by $0.04. The company had revenue of $715.40 million for the quarter, compared to analyst estimates of $685.24 million. Hologic had a net margin of 27.31% and a return on equity of 25.26%. Hologic’s revenue was up 3.2% compared to the same quarter last year. During the same period last year, the company posted $0.47 earnings per share.
A number of research analysts recently commented on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $49.00 target price on shares of Hologic in a research report on Wednesday, June 28th. Zacks Investment Research downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. Leerink Swann reaffirmed an “outperform” rating and issued a $52.00 target price on shares of Hologic in a research report on Thursday, March 30th. Needham & Company LLC increased their target price on shares of Hologic from $46.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, April 4th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $51.00 target price on shares of Hologic in a research report on Tuesday, March 14th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $47.54.
In related news, Director Lawrence M. Levy sold 10,757 shares of the firm’s stock in a transaction dated Wednesday, April 12th. The shares were sold at an average price of $42.45, for a total value of $456,634.65. Following the completion of the sale, the director now owns 24,596 shares in the company, valued at $1,044,100.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Lawrence M. Levy sold 2,960 shares of the firm’s stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $44.54, for a total transaction of $131,838.40. Following the completion of the sale, the director now owns 45,634 shares of the company’s stock, valued at approximately $2,032,538.36. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,148 shares of company stock worth $4,772,811. Insiders own 0.79% of the company’s stock.
Several hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. bought a new stake in shares of Hologic during the fourth quarter valued at approximately $37,017,000. Teachers Retirement System of The State of Kentucky boosted its stake in shares of Hologic by 309.0% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 137,829 shares of the medical equipment provider’s stock valued at $5,530,000 after buying an additional 104,129 shares during the period. Swiss National Bank boosted its stake in shares of Hologic by 23.4% in the first quarter. Swiss National Bank now owns 1,028,124 shares of the medical equipment provider’s stock valued at $43,747,000 after buying an additional 195,100 shares during the period. Lincoln Capital Corp bought a new stake in shares of Hologic during the fourth quarter valued at approximately $377,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Hologic by 0.7% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,949 shares of the medical equipment provider’s stock valued at $640,000 after buying an additional 104 shares during the period. Hedge funds and other institutional investors own 94.47% of the company’s stock.
Shares of Hologic (NASDAQ:HOLX) traded down 1.43% during trading on Wednesday, reaching $44.73. 1,063,315 shares of the company traded hands. Hologic has a 52 week low of $33.67 and a 52 week high of $46.80. The company has a market capitalization of $12.52 billion, a price-to-earnings ratio of 16.04 and a beta of 0.91. The firm’s 50 day moving average price is $44.35 and its 200-day moving average price is $42.22.
WARNING: “$0.49 EPS Expected for Hologic, Inc. (NASDAQ:HOLX) This Quarter” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2017/07/29/0-49-eps-expected-for-hologic-inc-nasdaqholx-this-quarter-updated-updated-updated.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.